将PLC重新命名为CelLBxHealth plc,重点是通过液体生物检查和CTC技术进行癌症研究。 Angle PLC rebrands to CelLBxHealth plc, focusing on cancer research via liquid biopsy and CTC technology.

2025年10月中旬,Agle PLC正在重新命名CelLBxHealth plc,任命Jan Groen博士为执行主席,重点研究肿瘤细胞(CTC)循环情报,用于肿瘤研究和药物开发。 Angle PLC is rebranding to CelLBxHealth plc by mid-October 2025, appointing Dr. Jan Groen as Executive Chairman to focus on circulating tumour cell (CTC) intelligence for oncology research and drug development. 通过利用Parsortix平台,这一转变强调液体生物切片、蛋白质组学和基因组学。 The shift emphasizes liquid biopsy, proteomics, and genomics, leveraging the Parsortix platform. 该公司旨在加强商业进步、控制成本和将其现金跑道扩大到2026年问题,并计划筹集额外资金。 The company aims to strengthen commercial progress, control costs, and extend its cash runway into Q1 2026, with plans to raise additional funding. Andrew Newland和Ian Griffiths将在明年过渡。 Andrew Newland and Ian Griffiths will transition out over the next year. AIM ticker 将更改为 CLBX, 并在仅供研究使用的框架下继续运行 。 The AIM ticker will change to CLBX, and operations continue under a research-use-only framework.